SCHEMBL5812872

SCHEMBL5812872

CCOC(=O)N1CCC2(CC1)OCc1cc(Br)ccc1O2

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.57
KMT2A Q03164 1/20 0.46
IDO1 P14902 13/20 0.46
ALDH1A1 P00352 2/20 0.43
HDAC3 O15379 2/20 0.42
HDAC4 P56524 2/20 0.42
HDAC1 Q13547 2/20 0.42
HDAC7 Q8WUI4 2/20 0.42
HDAC2 Q92769 2/20 0.42
HDAC10 Q969S8 2/20 0.42
HDAC11 Q96DB2 2/20 0.42
HDAC8 Q9BY41 2/20 0.42
HDAC6 Q9UBN7 2/20 0.42
HDAC9 Q9UKV0 2/20 0.42
HDAC5 Q9UQL6 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20270062 0.89 FAAH (0.46) FAAHKMT2AIDO1ALDH1A1HDAC3
SCHEMBL5917686 0.86 FAAH (0.56) FAAHIDO1
SCHEMBL5917702 0.85 KMT2A (0.50) KMT2AIDO1ALDH1A1HDAC3HDAC4
SCHEMBL5917710 0.83 FAAH (0.64) FAAHKMT2AALDH1A1
SCHEMBL11918667 0.83 SMN1; SMN2 (0.49) FAAHKMT2AALDH1A1
SCHEMBL20270215 0.81 KMT2A (0.42) FAAHKMT2AALDH1A1HDAC3HDAC4
SCHEMBL5917719 0.81 KMT2A (0.46) FAAHKMT2AIDO1ALDH1A1HDAC3
SCHEMBL25337245 0.79 IDO1 (0.49) KMT2AIDO1ALDH1A1HDAC3HDAC4
SCHEMBL11918449 0.79 KMT2A (0.43) FAAHKMT2AIDO1ALDH1A1HDAC3
SCHEMBL20270602 0.78 GPR119 (0.43) FAAHKMT2AALDH1A1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448392-B2 Spiropiperidine derivatives CEPHALON LLC (US) 2025-10-21 US disclosed
US-20240166661-A1 Spiropiperidine Derivatives CEPHALON LLC 2024-05-23 US disclosed
US-11878982-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2024-01-23 US disclosed
US-20210284651-A1 Spiropiperidine Derivatives CEPHALON LLC 2021-09-16 US disclosed
US-11046707-B2 Spiropiperidine derivatives 89BIO LTD (IL) 2021-06-29 US disclosed
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON LLC 2020-01-30 US disclosed
EP-3554637-A1 SPIROPIPERIDINE DERIVATIVES 89Bio Ltd. (IL) 2019-10-23 EP disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 WO disclosed
WO-2018112204-A1 SPIROPIPERIDINE DERIVATIVES CEPHALON, INC. (US) 2018-06-21 WO disclosed
US-8513232-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC. (US) 2013-08-20 US disclosed
US-8513232-B2 Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands CEPHALON, INC. (US) 2013-08-20 US disclosed
EP-2250176-B1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON INC (US) 2012-08-01 EP disclosed
US-20110071131-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-03-24 US disclosed
US-20110071131-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands CEPHALON, INC. (US) 2011-03-24 US disclosed
WO-2009097567-A1 SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS CEPHALON, INC. (US) 2009-08-06 WO disclosed
US-20060217375-A1 New compounds BIOVITRUM AB (SE) 2006-09-28 US disclosed
WO-2006067224-A2 SPIRO-BENZODIOXOLE AND SPIRO-BENZODIOXANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS BIOVITRUM AB (PUBL) (SE) 2006-06-29 WO disclosed
WO-2006067224-A2 SPIRO-BENZODIOXOLE AND SPIRO-BENZODIOXANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS BIOVITRUM AB (PUBL) (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11878982-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885
US-20110071131-A1 Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands HRH3, HRH4, HRH2 FAAH 325/4885KMT2A 840/4885IDO1 667/4885
US-20060217375-A1 New compounds HCRTR2, HCRTR1, NPY1R FAAH 352/4885KMT2A 858/4885IDO1 653/4885
US-20210284651-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885
US-20200031840-A1 SPIROPIPERIDINE DERIVATIVES FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885
US-12448392-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885
US-20240166661-A1 Spiropiperidine Derivatives FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885
US-11046707-B2 Spiropiperidine derivatives FASN, FADS2, SCD5 FAAH 335/4885KMT2A 4061/4885IDO1 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.